THE LONG DAWN

Dispatches / Heart & metabolism

Guarding the inner engine

Retatrutide reduced sleep apnea severity in two phase 3 trials

One weekly injection reshaping the body's metabolism, and with it the quiet emergencies of sleep.

Phase 3Peer-reviewed journal

What happened

  • TRIUMPH‑1-OSA (243 people) and TRIUMPH‑2-OSA (448 people, with type 2 diabetes) tested once-weekly retatrutide (Eli Lilly) against placebo in moderate-to-severe obstructive sleep apnea with obesity or overweight.
  • At 80 weeks, the 9 mg dose cut breathing interruptions by 24.4 events an hour more than placebo in TRIUMPH‑1-OSA, and 14.4 more in TRIUMPH‑2-OSA. Published in The New England Journal of Medicine.
  • Body weight fell 12% to 22% depending on dose and trial, versus about 5% with placebo.

What we don't know yet

  • Side effects were mostly gastrointestinal. Retatrutide is not approved.
  • Trial was funded by the maker.

Primary sources

Not medical advice. This is a summary of published results, not a recommendation. Ask your own doctor whether any treatment or trial fits you. To look for trials near you, search ClinicalTrials.gov or the WHO trial registry portal.